PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperparathyroidism |
| Phenotype | C0022661|chronic kidney disease |
| Sentences | 54 |
| PubMedID- 24202304 | Objective: calcitriol and various analogs are commonly used to suppress secondary hyperparathyroidism in chronic kidney disease but may also exacerbate vascular calcification. |
| PubMedID- 24402111 | [clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease]. |
| PubMedID- 21885174 | Background: the efficacy of 25-hydroxyvitamin d (25[oh]d) supplementation versus vitamin d receptor activators for the treatment of secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stages 3 or 4 and vitamin d deficiency is unclear. |
| PubMedID- 26411713 | The relation may guide physician to suspect hyperparathyroidism in chronic kidney disease patients and manage the complications related to hyperparathyroidism like renal mineral bone disease, anemia resistant to erythropoietin. |
| PubMedID- 21832979 | Alfacalcidol and paricalcitol are vitamin d analogs used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, but have known dose-dependent side effects that cause hypercalcemia and hyperphosphatemia. |
| PubMedID- 23140920 | Considering its low incidence rate of long-term relapse, "presumed" total parathyroidectomy without autotrasplantation (tp) may be indicated for secondary hyperparathyroidism (2hpt) in patients with chronic kidney disease (ckd), not eligible for kidney transplantation. |
| PubMedID- 22015443 | Background: the recently developed non-invasive high-intensity focussed ultrasound (hifu) technique for the destruction of parathyroid adenomas could also be of interest for the treatment of secondary hyperparathyroidism (shp) in patients with chronic kidney disease (ckd). |
| PubMedID- 22216316 | Additionally, poor nutritional status, vitamin d deficiency and hyperparathyroidism in patients with chronic kidney disease contribute to impaired immunity [6], [7]. |
| PubMedID- 22930877 | Secondary hyperparathyroidism in patients with chronic kidney disease (ckd) is common and usually caused by associated metabolic abnormalities, in particular, hypocalcaemia and hyperphosphataemia. |
| PubMedID- 25789142 | [15] in fact, a reduction in 1,25(oh) 2d secondary to reduced 1-α hydroxylase enzyme activity contributes to the development of secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 22007637 | Background: the calcimimetic cinacalcet is approved for treating secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. |
| PubMedID- 25028644 | The development of calcimimetics, which are synthetic allosteric modulators of the calcium-sensing receptor (car), has been a breakthrough in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (ckd). |
| PubMedID- 23703334 | Particular attention is paid on this topic in nephrology, because vitamin d is routinely used to treat secondary hyperparathyroidism in patients with chronic kidney diseases1236. |
| PubMedID- 21318141 | Until now superiority of the third generation of pth kits, measuring only the concentration of “native” 1-84-pth, has not been proven for diagnosis of primary hyperparathyroidism, at least in patients without chronic kidney disease. |
| PubMedID- 20090879 | The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) on dialysis. |
| PubMedID- 25949433 | This study aims to highlight the challenges in the diagnosis of hyperparathyroidism (hpt) in patients with advanced chronic kidney disease (ckd). |
| PubMedID- 23833757 | Purpose: the national kidney foundation kidney disease outcomes quality initiative (nkf-k/doqi) 2003 has established guidelines for the treatment of secondary hyperparathyroidism (shpt) in patients with chronic kidney disease - minerals and bone disorder (ckd-mbd). |
| PubMedID- 25950238 | Long-term outcomes of total parathyroidectomy with or without autoimplantation for hyperparathyroidism in chronic kidney disease: a meta-analysis. |
| PubMedID- 20435429 | Tptx should be considered a safe and successful procedure for the treatment of severe secondary hyperparathyroidism associated with chronic kidney disease. |
| PubMedID- 25446887 | Vitamin d insufficiency is prevalent in chronic kidney disease (ckd) and associated with secondary hyperparathyroidism (shpt) and increased risk of bone and vascular disease. |
| PubMedID- 26429172 | Vascular calcifications represent a severe complication of secondary hyperparathyroidism in patients with chronic kidney disease (ckd) stage 5. |
| PubMedID- 22868729 | [management of secondary hyperparathyroidism in patients with chronic kidney disease undergoing dialysis in togo]. |
| PubMedID- 25905209 | hyperparathyroidism in chronic kidney disease |
| PubMedID- 25384431 | Ch is thus currently used for the treatment of secondary hyperparathyroidism in chronic kidney disease (ckd) patients with satisfactory clinical effects [4, 5]. |
| PubMedID- 20056760 | Background and objectives: the optimal treatment of secondary hyperparathyroidism in chronic kidney disease (ckd) is unknown. |
| PubMedID- 23760489 | Synthetic analogs of 1,25(oh) 2d that are less calcemic, such as paricalcitol (19-nor-1,25-dihydroxyvitamin d 2), are used to treat hyperparathyroidism associated with chronic kidney disease. |
| PubMedID- 23330456 | The calcimimetic agent cinacalcet is approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma. |
| PubMedID- 22022934 | Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis. |
| PubMedID- 22293059 | Therefore, in everyday clinical practice, hypercalcemia and hyperphosphatemia often limits the ability to suppress secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 24089157 | High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in argentina. |
| PubMedID- 22997972 | Background: secondary hyperparathyroidism develops frequently with chronic kidney disease (ckd) and is associated with poor outcome. |
| PubMedID- 25701941 | Gene mutations in chronic kidney disease patients with secondary hyperparathyroidism and sagliker syndrome. |
| PubMedID- 21076444 | Secondary hyperparathyroidism in chronic kidney disease (ckd) develops in response to disturbances in calcium and phosphate metabolism associated with ckd, including fgf23 and klotho. |
| PubMedID- 22622503 | Moreover, during the past decade, the intense research on mineral disorders, seen in the course of chronic kidney disease with secondary hyperparathyroidism, has revealed the interplay between ca(2+) and mg(2+) homeostasis. |
| PubMedID- 25949409 | In 2004, the us food and drug administration (fda) approved cinacalcet-hcl (sensipar®, amgen) for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. |
| PubMedID- 23521343 | hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. |
| PubMedID- 22503212 | Background: cinacalcet (krn1493) was developed to manage secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 25490118 | Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. |
| PubMedID- 23222688 | In the context of a pharmacokinetic (pk)/pharmacodynamic study of cinacalcet in dialysis-dependent chronic kidney disease children with secondary hyperparathyroidism, we describe the development and validation of a new, rapid, simple, and economical liquid chromatography-tandem mass spectrometry (lc-ms/ms) micromethod for quantifying cinacalcet plasma concentrations. |
| PubMedID- 23877588 | Fgf-23 and secondary hyperparathyroidism in chronic kidney disease. |
| PubMedID- 22942242 | The calcium-sensing receptor (casr)-specific allosteric modulator cinacalcet has revolutionized the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. |
| PubMedID- 23018042 | In chronic kidney disease patients with secondary hyperparathyroidism (shpt), the recommended k/doqi target serum levels of parathyroid hormone (pth), calcium (ca) and phosphorus (p) are difficult to reach and maintain stable. |
| PubMedID- 21460359 | Diuretics and secondary hyperparathyroidism in chronic kidney disease. |
| PubMedID- 21058933 | Importance of the field: chronic kidney disease is frequently complicated by secondary hyperparathyroidism, which causes bone disease and vascular calcification, leading to increased risk of morbidity and mortality. |
| PubMedID- 26429790 | Surgical management of secondary hyperparathyroidism in chronic kidney disease-a consensus report of the european society of endocrine surgeons. |
| PubMedID- 25984155 | Hyperphosphataemia is an established risk factor for cardiovascular mortality, renal osteodystrophy and secondary hyperparathyroidism in patients with end-stage chronic kidney disease (ckd) under renal replacement therapy. |
| PubMedID- 23713879 | Paricalcitol is a synthetic vitamin d2 agonist of the vdr approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd). |
| PubMedID- 24884838 | This report describes the activity of amg 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease on dialysis. |
| PubMedID- 23960343 | This study was carried out to evaluate the efficacy and safety of doxercalciferol as therapy for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stage 4 in a prospective clinical trial. |
| PubMedID- 26306956 | Paricalcitol has proved effective to control secondary hyperparathyroidism in chronic kidney disease in both dialysed and non-dialysed patients, with a low hypercalcaemia incidence. |
Page: 1 2